Esperion Stock Downgraded Amid Merck’s Competitive Pressure
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
- Latest
- Trending
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.